Biomarker Analysis Services for Mitochondrial Disease
At Protheragen, we offer specialized biomarker analysis services dedicated to advancing Mitochondrial Disease research and therapeutic development. Our comprehensive biomarker panel is designed to elucidate the complex pathophysiology of mitochondrial disorders, supporting drug discovery and preclinical development. Please note that all our services are exclusively focused on research applications in drug discovery and preclinical stages; we do not provide clinical diagnostic services.
Effective therapeutic intervention for Mitochondrial Disease begins with robust biomarker discovery and identification. Protheragen's biomarker discovery services leverage cutting-edge technologies to identify molecular signatures associated with mitochondrial dysfunction. Our process includes high-throughput screening of candidate biomarkers, followed by validation studies to confirm their relevance in preclinical models. This approach accelerates the identification of potential drug targets and supports the rational design of therapeutic strategies.
Multi Omics: Protheragen employs a multi-omics approach, integrating genomics, transcriptomics, proteomics, and metabolomics to provide a comprehensive understanding of biological systems underlying Mitochondrial Disease. Through advanced sequencing, quantitative proteomics, and metabolite profiling, we identify DNA, RNA, protein, and metabolite biomarkers relevant to mitochondrial function and dysfunction. Our approach enables the detailed interrogation of disease-related pathways, such as mitochondrial DNA maintenance, oxidative phosphorylation, and lipid metabolism, providing a holistic view of disease mechanisms.
Candidate Validation: Our candidate validation strategies involve rigorous evaluation of biomarker associations with Mitochondrial Disease pathophysiology. Preliminary screening is conducted using in vitro and in vivo models, focusing on molecular features implicated in mitochondrial genome integrity, energy metabolism, and cellular stress responses. Criteria for prioritizing promising candidates include biological relevance, reproducibility, and potential to inform therapeutic development.
Diverse Technological Platforms: Protheragen offers custom assay development tailored to mitochondrial biomarker research, with platform adaptation to meet specific project requirements. Our technological platforms include immunoassays, mass spectrometry, flow cytometry, molecular diagnostic assays, and advanced histopathology and imaging systems, ensuring flexibility and precision for diverse biomarker targets.
Immunoassays: We develop and optimize enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, and multiplex immunoassays for sensitive and specific detection of protein biomarkers related to mitochondrial function.
Mass Spectrometry: Our LC-MS/MS platforms enable quantitative and qualitative analysis of proteins, peptides, and metabolites, supporting comprehensive profiling of mitochondrial pathways.
Flow Cytometry: We utilize flow cytometry for single-cell analysis of mitochondrial markers, enabling high-throughput phenotyping and functional assessment.
Molecular Diagnostics: Our molecular diagnostic capabilities encompass PCR-based and sequencing methods for detecting genetic variants and expression changes in mitochondrial and nuclear genes.
Histopathology And Imaging: Advanced histological and imaging techniques are employed to visualize mitochondrial alterations in tissues, supporting spatial and morphological biomarker analysis.
Rigorous Method Validation: All analytical methods undergo rigorous validation according to established research guidelines, including assessment of sensitivity, specificity, accuracy, precision, linearity, and reproducibility. Quality control measures are implemented throughout the workflow to ensure data integrity and reliability for preclinical research applications.
Protheragen provides quantitative analysis capabilities for biomarker measurement, enabling precise evaluation of molecular changes associated with Mitochondrial Disease. Our validated protocols support absolute and relative quantification across a range of sample types, facilitating robust data generation for drug discovery research.
Sample Analysis: We handle a wide spectrum of sample types, including cell lines, animal tissues, and biofluids relevant to preclinical mitochondrial research. Standardized protocols are applied to ensure consistent sample processing, and stringent quality measures are maintained to minimize pre-analytical variability.
High Throughput Capabilities: Our high-throughput analytical platforms support multiplexed biomarker analysis, maximizing efficiency and conserving valuable samples. Multiplexing strategies enable simultaneous measurement of multiple analytes, accelerating data acquisition and enhancing the depth of biological insights.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| DNA polymerase gamma, catalytic subunit (POLG) | DNA polymerase gamma, catalytic subunit (POLG), is the primary enzyme responsible for the replication and repair of mitochondrial DNA (mtDNA) in eukaryotic cells. POLG possesses both DNA polymerase and 3'-5' exonuclease activities, enabling it to synthesize new DNA strands and proofread for errors during mtDNA replication. It works as part of a heterotrimeric complex, with the catalytic subunit encoded by the POLG gene and two accessory subunits encoded by POLG2. Proper function of POLG is essential for the maintenance of mitochondrial genome integrity, and mutations in POLG can lead to compromised mitochondrial function and a range of mitochondrial diseases. | POLG has been utilized as a biomarker primarily in the context of mitochondrial disorders. Mutations or alterations in the POLG gene are associated with a spectrum of mitochondrial diseases, including progressive external ophthalmoplegia, Alpers-Huttenlocher syndrome, and mitochondrial DNA depletion syndromes. Detection of POLG mutations can aid in the diagnosis of these conditions, inform prognosis, and guide clinical management. Additionally, POLG mutation analysis is used in the evaluation of patients with unexplained neurological, hepatic, or myopathic symptoms suggestive of mitochondrial dysfunction. |
| fatty acid synthase (FASN) | Fatty acid synthase (FASN) is a multi-enzyme protein complex that catalyzes the de novo synthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA in the presence of NADPH. FASN plays a central role in lipid biosynthesis, particularly in the conversion of dietary carbohydrates into fatty acids, which are then used for energy storage, membrane synthesis, and the production of signaling molecules. FASN activity is tightly regulated in normal tissues, with high expression in lipogenic tissues such as liver, adipose tissue, and lactating mammary gland, while most adult tissues exhibit low expression. | FASN expression has been reported to be elevated in various malignancies, including breast, prostate, ovarian, and lung cancers. Its overexpression is associated with increased lipogenesis in tumor cells, which supports rapid cell proliferation and survival. As such, FASN has been utilized as a biomarker for the detection and characterization of certain cancers, and its expression levels have been studied in relation to tumor grade, prognosis, and response to therapy. Additionally, FASN has been explored as a potential marker for metabolic disorders, given its role in lipid metabolism. |
| insulin (INS) | Insulin (INS) is a peptide hormone produced by the beta cells of the pancreatic islets. Its primary biological function is to regulate glucose homeostasis. Insulin facilitates the uptake of glucose into adipose tissue, muscle, and other cells, thereby lowering blood glucose levels. It promotes glycogen synthesis in the liver and muscle, inhibits gluconeogenesis and glycogenolysis, and plays roles in lipid and protein metabolism by promoting lipid synthesis and inhibiting lipolysis and proteolysis. Insulin signaling involves binding to the insulin receptor, triggering a cascade of intracellular events that mediate its metabolic effects. | Insulin is widely used as a biomarker in the assessment of metabolic function and disorders. Measurement of circulating insulin levels can assist in the evaluation of pancreatic beta-cell function, insulin resistance, and the pathophysiology of diabetes mellitus. It is commonly measured in fasting and postprandial states, as well as during glucose tolerance and insulin tolerance tests. Insulin levels are also utilized in research and clinical settings to study metabolic syndrome, hyperinsulinemia, and related endocrine disorders. |
| mitochondrially encoded cytochrome c oxidase I (COX1) | Mitochondrially encoded cytochrome c oxidase I (COX1) is a subunit of cytochrome c oxidase (complex IV), the terminal enzyme complex of the mitochondrial electron transport chain. COX1 is encoded by the mitochondrial genome and is integral to the inner mitochondrial membrane. It plays a central role in the transfer of electrons from cytochrome c to molecular oxygen, facilitating the reduction of oxygen to water. This process contributes to the generation of a proton gradient across the inner mitochondrial membrane, which is then used by ATP synthase to produce ATP during oxidative phosphorylation. COX1 is essential for efficient cellular energy production and is highly conserved across eukaryotic species. | COX1 is widely utilized as a molecular marker in species identification and phylogenetic studies, particularly in animals. Its genetic sequence is commonly used in DNA barcoding, a method for identifying and distinguishing species based on short, standardized genetic regions. The high interspecific variability and low intraspecific variability of the COX1 gene make it suitable for distinguishing closely related species. COX1 barcoding is extensively applied in taxonomy, biodiversity assessment, ecological monitoring, and food authentication. Additionally, COX1 sequence analysis can assist in detecting contamination and mislabeling in biological samples. |
| sirtuin 1 (SIRT1) | Sirtuin 1 (SIRT1) is a NAD+-dependent deacetylase that belongs to the sirtuin family of proteins. SIRT1 regulates a variety of cellular processes through the deacetylation of histones and numerous non-histone proteins, including transcription factors and enzymes. Its biological functions include modulation of metabolism, stress response, DNA repair, inflammation, and cellular senescence. SIRT1 is involved in the regulation of energy homeostasis, mitochondrial biogenesis, and circadian rhythm. It plays a role in the cellular response to caloric restriction and oxidative stress, and is implicated in the regulation of cell survival, apoptosis, and aging-related pathways. | SIRT1 expression and activity levels have been studied in various physiological and pathological contexts, including metabolic disorders, neurodegenerative diseases, cardiovascular diseases, and certain cancers. Changes in SIRT1 levels or activity in tissues or body fluids have been investigated as potential indicators of disease state, progression, or response to therapy. For example, altered SIRT1 expression has been associated with metabolic syndrome, type 2 diabetes, and neurodegenerative conditions such as Alzheimer's disease. Measurement of SIRT1 has been explored in research settings as a potential biomarker for disease risk stratification, prognosis, and monitoring of therapeutic interventions. |
Explore Research Opportunities with Protheragen. Our biomarker research services for Mitochondrial Disease leverage advanced analytical platforms and a comprehensive biomarker panel to support exploratory preclinical research. All biomarkers discussed are research targets only; we do not claim any biomarkers as validated or mandatory for any application. Our focus is on preclinical research stages, and we maintain scientific objectivity throughout our collaborative projects.
We invite you to discuss exploratory biomarker research collaborations with Protheragen. Connect with us to exchange scientific insights and explore research-driven approaches to understanding mitochondrial disease biology.
Make Order
Experimental Scheme
Implementation
Conclusion
